Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CGN-006
- Development stage
- Preclinical
- Lead developer
- CitraGen Pharmaceuticals
- Modality
- Small Molecules
01
Overview
CGN-006 is a preclinical drug candidate developed by CitraGen Pharmaceuticals, specifically targeting orphan indications within the field of nephrology. As part of CitraGen's pipeline of New Chemical Entities (NCEs) and complex specialty products, CGN-006 is being evaluated for its potential to treat rare kidney-related disorders. Detailed information regarding its specific molecular target, modality, and mechanism of action remains proprietary as the asset progresses through early-stage development. The company's broader focus in renal care includes managing electrolyte and mineral imbalances, suggesting CGN-006 may address a niche metabolic or physiological aspect of rare renal pathology.
Beyond the preview
Go deeper on CGN-006.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CGN-006.